Phase I data released from study of Lymphir dosing prior to commercial CAR T therapy in high‑risk diffuse large b‑cell lymphoma

Oncology has a semantics problem: How do we define “early stage”?

I recently found myself asking a question that I thought had an obvious answer: What is early-stage cancer?

October 09, 2026

NIH introduces “Linked Discoveries,” a PubMed tool aimed at strengthening research replication, reproducibility

NIH has introduced Linked Discoveries, an experimental tool designed to help scientists more easily see how an individual research finding relates to the larger body of biomedical evidence.

October 02, 2026

Vol.52 No.36

In Brief

ARPA-H launches SURPASS program to accelerate clinical trials

ARPA-H launched the Simulation-augmented, Real-time Platform Adaptive Seamless Trials (SURPASS) program, together with three complementary projects, aimed at removing barriers that slow clinical development and help promising treatments reach patients sooner.

October 02, 2026

Vol.52 No.36

Clinical Roundup

City of Hope’s “plug-and-play” CAR T platform lets researchers update cells after infusion

Researchers from City of Hope have developed a “plug-and-play” technology that adds engineered molecules to chimeric antigen receptor T cells after treatment, allowing scientists to better control the cells and redirect them to attack different types of cancer. The preclinical study offers a more flexible way to help CAR T cells keep pace with mutating tumors.

October 02, 2026

Vol.52 No.36

Clinical Roundup

Mount Sinai-led study identifies why some patients develop severe intestinal inflammation after CAR T therapy

Researchers at the Icahn School of Medicine at Mount Sinai have identified biological mechanisms that may contribute to CAR T-cell-associated enterocolitis, a serious inflammatory condition of the intestine that can occur after a type of CAR T cell therapy for multiple myeloma.

October 02, 2026

Vol.52 No.36

Clinical Roundup

Tagrisso increased OS in early-stage EGFR-mutated lung cancer at eight year follow-up, ADAURA phase III trial finds

Tagrisso (osimertinib) demonstrated a sustained, clinically meaningful overall survival benefit at eight years compared to placebo in the adjuvant treatment of patients with early-stage (1B, 2, and 3A) epidermal growth factor receptor-mutated non-small cell lung cancer after complete tumor resection with curative intent, according to the updated exploratory results from the ADAURA phase III trial.

September 25, 2026

Vol.52 No.35

Phase I data released from study of Lymphir dosing prior to commercial CAR T therapy in high‑risk diffuse large b‑cell lymphoma

YOU MAY BE INTERESTED IN

Oncology has a semantics problem: How do we define “early stage”?

NIH introduces “Linked Discoveries,” a PubMed tool aimed at strengthening research replication, reproducibility

ARPA-H launches SURPASS program to accelerate clinical trials

City of Hope’s “plug-and-play” CAR T platform lets researchers update cells after infusion

Mount Sinai-led study identifies why some patients develop severe intestinal inflammation after CAR T therapy

Tagrisso increased OS in early-stage EGFR-mutated lung cancer at eight year follow-up, ADAURA phase III trial finds

Renew today!

Subscriber content

Never miss an issue!

Login